07/02/2024: VIS, Inc. receives a $4,950,000 structured equity investment to finance US and Canadian operations including clinical site initiation, regulatory efforts, and system manufacturing.
05/03/2024: VIS, Inc. launches patient screening for the Opti-K™ Phase IIIa Pivotal Study
05/01/2024: VIS, Inc. releases a US$10MM Private Placement Memorandum (PPM) Class D Preferred Convertible for Accredited investors
04/17/2024: VIS LLC, a Texas Limited Liability Company, converts to VIS, Inc., a Texas C-Corporation
01/01/2024: Cataract & Refractive Surgery Today (CRST) A New Approach to Thermal Keratoplasty
12/20/2023: Health Canada Approves The Opti-K™ Investigational Testing Authorization (ITA) For the Treatment of Dry Age Related Macular Degeneration (AMD)
04/19/23: FDA Approves The Opti-K™ Investigational Device Exemption (IDE) For The Phase III FDA Pivotal Study For the Treatment of Presbyopia
